These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 19957540

  • 1. Studies on formulation development of mouth dissolving tablets of Carvedilol.
    Pokharkar V, Dhar S, Mandpe L.
    Hindustan Antibiot Bull; ; 49-50(1-4):21-8. PubMed ID: 19957540
    [Abstract] [Full Text] [Related]

  • 2. Ternary complexation of carvedilol, beta-cyclodextrin and citric acid for mouth-dissolving tablet formulation.
    Pokharkar V, Khanna A, Venkatpurwar V, Dhar S, Mandpe L.
    Acta Pharm; 2009 Jun; 59(2):121-32. PubMed ID: 19564138
    [Abstract] [Full Text] [Related]

  • 3. Cyclodextrin-containing poly(ethyleneoxide) tablets for the delivery of poorly soluble drugs: potential as buccal delivery system.
    Cappello B, De Rosa G, Giannini L, La Rotonda MI, Mensitieri G, Miro A, Quaglia F, Russo R.
    Int J Pharm; 2006 Aug 17; 319(1-2):63-70. PubMed ID: 16650700
    [Abstract] [Full Text] [Related]

  • 4. Preparation and in vitro characterization of non-effervescent floating drug delivery system of poorly soluble drug, carvedilol phosphate.
    Srikanth Meka V, Wee Liang VA, Dharmalingham SR, Sheshala R, Gorajana A.
    Acta Pharm; 2014 Dec 17; 64(4):485-94. PubMed ID: 25531788
    [Abstract] [Full Text] [Related]

  • 5. Formulation development of carvedilol compression coated tablet.
    Shah R, Patel S, Patel H, Pandey S, Shah S, Shah D.
    Pharm Dev Technol; 2013 Dec 17; 18(4):906-15. PubMed ID: 21797662
    [Abstract] [Full Text] [Related]

  • 6. Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits.
    Aljimaee YH, El-Helw AR, Ahmed OA, El-Say KM.
    Drug Des Devel Ther; 2015 Dec 17; 9():1379-92. PubMed ID: 25834396
    [Abstract] [Full Text] [Related]

  • 7. Tracking of crystalline-amorphous transition of carvedilol in rotary spun microfibers and their formulation to orodispersible tablets for in vitro dissolution enhancement.
    Szabó P, Sebe I, Stiedl B, Kállai-Szabó B, Zelkó R.
    J Pharm Biomed Anal; 2015 Nov 10; 115():359-67. PubMed ID: 26280924
    [Abstract] [Full Text] [Related]

  • 8. Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations.
    Yedurkar P, Dhiman MK, Petkar K, Sawant K.
    J Microencapsul; 2012 Nov 10; 29(2):126-37. PubMed ID: 22047549
    [Abstract] [Full Text] [Related]

  • 9. Systematic development of pH-independent controlled release tablets of carvedilol using central composite design and artificial neural networks.
    Aktas E, Eroglu H, Kockan U, Oner L.
    Drug Dev Ind Pharm; 2013 Aug 10; 39(8):1207-16. PubMed ID: 22804226
    [Abstract] [Full Text] [Related]

  • 10. Design and in vivo evaluation of carvedilol buccal mucoadhesive patches.
    Thimmasetty J, Pandey G, Babu P.
    Pak J Pharm Sci; 2008 Jul 10; 21(3):241-8. PubMed ID: 18614419
    [Abstract] [Full Text] [Related]

  • 11. Investigations of a novel self-emulsifying osmotic pump tablet containing carvedilol.
    Wei L, Li J, Guo L, Nie S, Pan W, Sun P, Liu H.
    Drug Dev Ind Pharm; 2007 Sep 10; 33(9):990-8. PubMed ID: 17891586
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of carvedilol solubility by solid dispersion technique using cyclodextrins, water soluble polymers and hydroxyl acid.
    Yuvaraja K, Khanam J.
    J Pharm Biomed Anal; 2014 Aug 05; 96():10-20. PubMed ID: 24705456
    [Abstract] [Full Text] [Related]

  • 13. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol.
    Singh B, Singh R, Bandyopadhyay S, Kapil R, Garg B.
    Colloids Surf B Biointerfaces; 2013 Jan 01; 101():465-74. PubMed ID: 23010056
    [Abstract] [Full Text] [Related]

  • 14. Tablet formulation studies on an oxcarbazepine-beta cyclodextrin binary system.
    Patel NV, Chotai NP, Patel MP.
    Pharmazie; 2008 Apr 01; 63(4):275-81. PubMed ID: 18468386
    [Abstract] [Full Text] [Related]

  • 15. Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential.
    Singh B, Khurana L, Bandyopadhyay S, Kapil R, Katare OO.
    Drug Deliv; 2011 Nov 01; 18(8):599-612. PubMed ID: 22008038
    [Abstract] [Full Text] [Related]

  • 16. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM, Elkheshen SA, Ghorab MM.
    Eur J Pharm Biopharm; 2008 Nov 01; 70(3):819-27. PubMed ID: 18655829
    [Abstract] [Full Text] [Related]

  • 17. Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction.
    Sica DA.
    Am J Cardiol; 2006 Oct 02; 98(7A):1L-4L. PubMed ID: 17023226
    [No Abstract] [Full Text] [Related]

  • 18. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes.
    Cirri M, Rangoni C, Maestrelli F, Corti G, Mura P.
    Drug Dev Ind Pharm; 2005 Aug 02; 31(7):697-707. PubMed ID: 16207617
    [Abstract] [Full Text] [Related]

  • 19. Carboxylated mesoporous carbon microparticles as new approach to improve the oral bioavailability of poorly water-soluble carvedilol.
    Zhang Y, Zhi Z, Li X, Gao J, Song Y.
    Int J Pharm; 2013 Sep 15; 454(1):403-11. PubMed ID: 23850816
    [Abstract] [Full Text] [Related]

  • 20. Development of orally disintegrating tablets of Perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex.
    Wang L, Zeng F, Zong L.
    Pharm Dev Technol; 2013 Sep 15; 18(5):1101-10. PubMed ID: 22759202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.